OncoCyte Corporation (NASDAQ:OCX) Q4 2022 Earnings Conference Call April 3, 2023 8:30 AM ET Company Participants Caroline Corner - Investor Relations, Westwicke Joshua Riggs - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants Tyler Anderson - Piper Sandler Mark Massaro - BTIG Joseph Conway - Needham & Company Mason Carrico - Stephens Inc Bruce Jackson - The Benchmark Company David Westenberg - Piper Sandler Operator Good day and welcome to the OncoCyte ...

OncoCyte Corporation (NASDAQ:OCX) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations Ronnie Andrews - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Mark Massaro - BTIG Thomas Flaten - Lake Street Mason Carrico - Stephens Bruce Jackson - Benchmark Company Operator Good day, and welcome to the OncoCyte Conference Call to discuss the Third Quarter 2022 F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or other ...

OncoCyte Corporation (NASDAQ:OCX) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Caroline Corner - Westwicke, Investor Relations Ronnie Andrews - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Mike Mattson - Needham & Company Mason Carrico - Stephens Operator Good day, and welcome to the OncoCyte Conference Call to discuss the Second Quarter 2022 Financial Results. Today's call is bein ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or othe ...

OncoCyte Corporation (NASDAQ:OCX) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ronnie Andrews – President and Chief Executive Officer Mitch Levine – Chief Financial Officer Troy Williams – LifeSci Advisors Conference Call Participants Mike Matson – Needham & Company Mark Massaro – BTIG David Westenberg – Piper Sandler Paul Knight – KeyBanc Capital Markets Thomas Flaten – Lake Street Capital Markets Mason Carrico – Stephens Inc. Bruce Jackson – The Benchmark Company Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Q42021 Financial Results & Operating Highlights HONCOCYTE Where Tomorrow LIVES March 10, 2022 Forward Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the anticipated revenue impact, value creation roadmap, expected market differentiatio ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Troy Williams - LifeSci Advisors Ronnie Andrews - President and Chief Executive Officer Mitch Levine - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham & Company David Westenberg - Piper Sandler Mason Carrico - Stephens Paul Knight - KeyBanc Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The Benchmark Company Operator Greetings. Welcome ...